Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Plasma cell 1

Conditions

Lung Neoplasms 2Multiple Myeloma 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × Aging × Clear all
NCT04825912 2024-02-02

SST Resilience

Duke University

Phase NA Completed
18 enrolled 14 charts
Thoracic

Lung Neoplasms

NCT04057196 2022-08-03

Self-System Therapy for Older Adults With Lung Cancer

Duke University

Phase NA Completed
30 enrolled 22 charts
Thoracic

Lung Neoplasms

NCT00807599 2019-03-15

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
67 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡